@ARTICLE{Włodarczyk_Jakub_Experimental_2021,
 author={Włodarczyk, Jakub and Szałwińska, Patrycja and Waśniewska, Anna and Fichna, Jakub},
 volume={Vol. 61},
 number={No 1},
 journal={Folia Medica Cracoviensia},
 pages={5-17},
 howpublished={online},
 year={2021},
 publisher={Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum},
 abstract={Irritable bowel syndrome (IBS) is a multifactorial gastrointestinal disorder with still not fully understood pathogenesis. At first, the treatment of IBS was mainly focused on alleviating symptoms (with the use of laxatives, anti-diarrheals, anti-spasmodics and painkillers) and then became more specific by targeting discovered pathways responsible for proper functioning of the gastrointestinal system, for in-stance: 5HT3, 5HT4, cannabinoid and opioid receptors, guanylyl cyclase C, chloride channels and sodium- hydrogen exchanger. Nowadays, there is a growing number of experimental IBS treatment strategies and in this article we discuss these novel and therapeutic options in IBS, their efficacy and future perspectives.},
 type={Article},
 title={Experimental therapies in Irritable Bowel Syndrome},
 URL={http://journals.pan.pl/Content/120117/2021-01-FMC-01-Wlodarczyk.pdf},
 doi={10.24425/fmc.2021.137209},
 keywords={irritable bowel syndrome, experimental, treatment, drugs, novel therapeutic approach},
}